CITATION REPORT List of articles citing

Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study

DOI: 10.1001/jamaneurol.2017.3949 JAMA Neurology, 2018, 75, 279-286.

Source: https://exaly.com/paper-pdf/69135286/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
705	Epilepsy. 2018 , 4, 18024		269
704	Different ketogenesis strategies lead to disparate seizure outcomes. 2018 , 143, 90-97		2
703	Error in Data Presentation. <i>JAMA Neurology</i> , 2018 , 75, 384	17.2	
702	In the Clinic-Epilepsy. 2018 , 18, 1		
701	Treatment of epilepsy - towards precision. 2018 , 7,		6
700	Drug Resistant Epilepsy and New AEDs: Two Perspectives. 2018 , 18, 304-306		4
699	From molecules to medicines: the dawn of targeted therapies for genetic epilepsies. 2018 , 14, 735-745		33
698	Histopathology of ~10,000 (Yes, That's TEN THOUSAND) Brain Tissue Samples From Epilepsy Surgery. 2018 , 18, 101-103		1
697	Response to treatment schedules after the first antiepileptic drug failed. 2018 , 59, 2118-2124		12
696	Seizure pathways: A model-based investigation. 2018 , 14, e1006403		13
695	Subcentimeter epilepsy surgery targets by resting state functional magnetic resonance imaging can improve outcomes in hypothalamic hamartoma. 2018 , 59, 2284-2295		34
694	Cannabis and epilepsy. 2018 , 18, 465-471		10
693	Epilepsy wellness: The standard of care for the 21st century. 2018 , 87, 241-242		
692	Mobile Software as a Medical Device (SaMD) for the Treatment of Epilepsy: Development of Digital Therapeutics Comprising Behavioral and Music-Based Interventions for Neurological Disorders. 2018 , 12, 171		17
691	Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. 2018 , 8, 10154		29
690	Biochemical autoregulatory gene therapy for focal epilepsy. 2018 , 24, 1324-1329		34
689	Vagus nerve stimulation (VNS) therapy update. 2018 , 88S, 2-10		76

688	The Expanding Role of Ketogenic Diets in Adult Neurological Disorders. 2018, 8,	46
687	Expected Budget Impact and Health Outcomes of Expanded Use of Vagus Nerve Stimulation Therapy for Drug-Resistant Epilepsy. 2018 , 35, 1686-1696	13
686	Knowledge, expectations and fears of cannabis use of epilepsy patients at a tertiary epilepsy center. 2019 , 99, 106458	5
685	Predicting Response to Treatment of Epileptic Seizures: How Much Time and How Many AEDs Do We Need to Try?. 2019 , 19, 299-301	
684	Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources. 2021 , 121, 106430	13
683	How do we choose the appropriate animal model for antiseizure therapy development?. 2019 , 14, 947-951	10
682	The 4-Aminopyridine Model of Acute Seizures Elucidates Efficacy of New Antiepileptic Drugs. 2019 , 13, 677	10
681	Clinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy. 2019 , 156, 106165	9
680	Use of complementary and alternative medicine among adults with epilepsy in a university epilepsy clinic in Poland. 2019 , 98, 40-44	2
679	Approach Angle Affects Accuracy in Robotic Stereoelectroencephalography Lead Placement. 2019 , 128, e322-e328	11
678	Revealing epilepsy type using a computational analysis of interictal EEG. 2019 , 9, 10169	9
677	PET imaging of metabolic changes after neural stem cells and GABA progenitor cells transplantation in a rat model of temporal lobe epilepsy. 2019 , 46, 2392-2397	5
676	The Epilepsy Surgery Grading Scale: Validation in an independent population with drug-resistant focal epilepsy. 2019 , 60, e78-e82	2
675	The Efficacy of Ketogenic Diet in 60 Chinese Patients With Dravet Syndrome. 2019 , 10, 625	13
674	Pyridox (am) ine 5'-phosphate oxidase deficiency induces seizures in Drosophila melanogaster. 2019 , 28, 3126-3136	7
673	Novel therapies for epilepsy in the pipeline. 2019 , 97, 282-290	16
672	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. 2019 , 4, 420-430	18
671	TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101. 2019 , 6, 2164-2174	7

670	Effectiveness of perampanel as a first add-on antiepileptic drug for the treatment of partial epilepsy. 2019 , 100, 106492	5
669	Genomic and clinical predictors of lacosamide response in refractory epilepsies. 2019 , 4, 563-571	8
668	CXCR7 regulates epileptic seizures by controlling the synaptic activity of hippocampal granule cells. 2019 , 10, 825	9
667	Treatment response and predictors in patients with newly diagnosed epilepsy in Ethiopia: a retrospective cohort study. 2019 , 9, 16254	3
666	Quantification and Selection of Ictogenic Zones in Epilepsy Surgery. 2019 , 10, 1045	10
665	Regression of Epileptogenesis by Inhibiting Tropomyosin Kinase B Signaling following a Seizure. 2019 , 86, 939-950	3
664	When can we trust responders? Serious concerns when using 50% response rate to assess clinical trials. 2019 , 60, e99-e103	9
663	Mode-Dependent Effect of Xenon Inhalation on Kainic Acid-Induced Status Epilepticus in Rats. 2019 , 13, 375	4
662	Dravet Syndrome: Early Diagnosis and Emerging Therapies. 2019 , 08, 031-037	
661		
001	Novel Optogenetic Approaches in Epilepsy Research. 2019 , 13, 947	11
660	Novel Optogenetic Approaches in Epilepsy Research. 2019, 13, 947 Xenon exerts anti-seizure and neuroprotective effects in kainic acid-induced status epilepticus and neonatal hypoxia-induced seizure. 2019, 322, 113054	9
	Xenon exerts anti-seizure and neuroprotective effects in kainic acid-induced status epilepticus and	
660	Xenon exerts anti-seizure and neuroprotective effects in kainic acid-induced status epilepticus and neonatal hypoxia-induced seizure. 2019 , 322, 113054 Prospective observational study: Fast ripple localization delineates the epileptogenic zone. 2019 ,	9
660 659	Xenon exerts anti-seizure and neuroprotective effects in kainic acid-induced status epilepticus and neonatal hypoxia-induced seizure. 2019 , 322, 113054 Prospective observational study: Fast ripple localization delineates the epileptogenic zone. 2019 , 130, 2144-2152	9
660 659 658	Xenon exerts anti-seizure and neuroprotective effects in kainic acid-induced status epilepticus and neonatal hypoxia-induced seizure. 2019, 322, 113054 Prospective observational study: Fast ripple localization delineates the epileptogenic zone. 2019, 130, 2144-2152 Co-medication and potential drug interactions among patients with epilepsy. 2019, 66, 47-52	9 11 13
660 659 658	Xenon exerts anti-seizure and neuroprotective effects in kainic acid-induced status epilepticus and neonatal hypoxia-induced seizure. 2019, 322, 113054 Prospective observational study: Fast ripple localization delineates the epileptogenic zone. 2019, 130, 2144-2152 Co-medication and potential drug interactions among patients with epilepsy. 2019, 66, 47-52 [Emergency management and medical care of adults with first epileptic seizures]. 2019, 144, 83-92	9 11 13
660 659 658 657	Xenon exerts anti-seizure and neuroprotective effects in kainic acid-induced status epilepticus and neonatal hypoxia-induced seizure. 2019, 322, 113054 Prospective observational study: Fast ripple localization delineates the epileptogenic zone. 2019, 130, 2144-2152 Co-medication and potential drug interactions among patients with epilepsy. 2019, 66, 47-52 [Emergency management and medical care of adults with first epileptic seizures]. 2019, 144, 83-92 Epilepsy in adults. 2019, 393, 689-701	9 11 13 0 429

(2019-2019)

652	Advancing research toward faster diagnosis, better treatment, and end of stigma in epilepsy. 2019 , 60, 1281-1292	11
651	The Concept of Drug-Resistant Epileptogenic Zone. 2019 , 10, 558	5
650	Milk-whey diet substantially suppresses seizure-like phenotypes of , a voltage-gated sodium channel mutant. 2019 , 33, 164-178	7
649	Pharmacological outcomes in teenagers with newly diagnosed epilepsy: A 30-year cohort study. 2019 , 60, 1083-1090	5
648	How long would it take to try all the antiepileptic drugs available?. 2019 , 154, 77-78	24
647	Long term seizure freedom on perampanel in highly drug-resistant epilepsy caused by bilateral periventricular nodular heterotopia: A case report. 2019 , 11, 99-102	1
646	Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. 2019 , 855, 175-182	49
645	Cerebral aquaporin-4 expression is independent of seizures in tuberous sclerosis complex. 2019 , 129, 93-101	3
644	Neural response to stress and perceived stress differ in patients with left temporal lobe epilepsy. 2019 , 40, 3415-3430	7
6.10		
643	Pharmacologic Management of Patients with Neurologic Disorders. 2019 , 69-84	
642	A scale for prediction of response to AEDs in patients with MRI-negative epilepsy. 2019 , 94, 41-46	3
		3 28
642	A scale for prediction of response to AEDs in patients with MRI-negative epilepsy. 2019 , 94, 41-46 Embelin Prevents Seizure and Associated Cognitive Impairments in a Pentylenetetrazole-Induced	
642	A scale for prediction of response to AEDs in patients with MRI-negative epilepsy. 2019 , 94, 41-46 Embelin Prevents Seizure and Associated Cognitive Impairments in a Pentylenetetrazole-Induced Kindling Zebrafish Model. 2019 , 10, 315	28
642 641 640	A scale for prediction of response to AEDs in patients with MRI-negative epilepsy. 2019 , 94, 41-46 Embelin Prevents Seizure and Associated Cognitive Impairments in a Pentylenetetrazole-Induced Kindling Zebrafish Model. 2019 , 10, 315 Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. 2019 , 96, 24-29	28
642 641 640 639	A scale for prediction of response to AEDs in patients with MRI-negative epilepsy. 2019, 94, 41-46 Embelin Prevents Seizure and Associated Cognitive Impairments in a Pentylenetetrazole-Induced Kindling Zebrafish Model. 2019, 10, 315 Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. 2019, 96, 24-29 "Are We There Yet?" Quest for Treatment of Refractory Epilepsy. 2019, 19, 57-58 Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus	28
642 641 640 639	A scale for prediction of response to AEDs in patients with MRI-negative epilepsy. 2019, 94, 41-46 Embelin Prevents Seizure and Associated Cognitive Impairments in a Pentylenetetrazole-Induced Kindling Zebrafish Model. 2019, 10, 315 Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. 2019, 96, 24-29 "Are We There Yet?" Quest for Treatment of Refractory Epilepsy. 2019, 19, 57-58 Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus on Epileptogenesis and Associated Comorbidities. 2019, 10, 119	28

634	Contemporary Dental Pharmacology. 2019 ,	1
633	Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records. 2019 , 9, e032551	11
632	Targeted knockout of GABA-A receptor gamma 2 subunit provokes transient light-induced reflex seizures in zebrafish larvae. 2019 , 12,	11
631	Cingulate seizures and recent treatment strategies. 2019 , 166, 341-353	1
630	Inhibition of epileptiform activity by neuropeptide Y in brain tissue from drug-resistant temporal lobe epilepsy patients. 2019 , 9, 19393	17
629	Long-term seizure freedom following intracranial sEEG monitoring: Therapeutic benefit of a diagnostic technique. 2019 , 12, 100345	4
628	Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors. 2019 , 26, 856-864	34
627	Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures. 2019 , 15, 93-102	7
626	Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate. 2019 , 29, 138-142	3
625	Treatment of epilepsy in light of the most recent advances. 2019 , 18, 7-8	5
624	Innovative approaches reaching underserved and rural communities to improve epilepsy care: A review of the methodology of the Connectors Project. 2019 , 90, 273-283	7
623	High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches. 2019 , 151, 542-557	51
622	Teamwork aids management and raises new issues in epilepsy. 2019 , 15, 66-67	1
621	Closed-Loop Brain Stimulation for Drug-Resistant Epilepsy: Towards an Evidence-Based Approach to Personalized Medicine. 2019 , 16, 119-127	35
620	Seizures and Epilepsy. 2019 , 103, 309-324	38
619	Prognosis of poststroke epilepsy. 2020 , 104, 106273	3
618	Pharmacoresistance - Epidemiology, mechanisms, and impact on epilepsy treatment. 2020 , 168, 107790	36
617	Aspects of cAMP Signaling in Epileptogenesis and Seizures and Its Potential as Drug Target. 2020 , 45, 1247-1255	5

616	Optogenetic and chemogenetic therapies for epilepsy. 2020 , 168, 107751	27
615	Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. 2020 , 19, 38-48	79
614	Preclinical evaluation of 1,2,4-triazole-based compounds targeting voltage-gated sodium channels (VGSCs) as promising anticonvulsant drug candidates. 2020 , 94, 103355	16
613	Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening. 2020 , 167, 107750	18
612	Predicting the antiepileptic drug response by brain connectivity in newly diagnosed focal epilepsy. 2020 , 267, 1179-1187	10
611	Vagus nerve stimulation for drug-resistant epilepsy. 2020 , 20, 189-198	9
610	Cenobamate: new hope for treatment-resistant epilepsy. 2020 , 19, 23-24	7
609	Molecular genetic management of epilepsy. 2020 , 289-308	
608	Serotonin and sudden unexpected death in epilepsy. 2020 , 325, 113145	25
607	GABA bouton subpopulations in the human dentate gyrus are differentially altered in mesial temporal lobe epilepsy. 2020 , 123, 392-406	10
607		10
,	Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive	
606	Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs. 2020 , 102, 106634	2
606	Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs. 2020, 102, 106634 First add-on perampanel for focal-onset seizures: An open-label, prospective study. 2020, 141, 132-140 The current approach of the Epilepsy Therapy Screening Program contract site for identifying	2
606	Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs. 2020, 102, 106634 First add-on perampanel for focal-onset seizures: An open-label, prospective study. 2020, 141, 132-140 The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. 2020, 166, 107811 Influence of new versus traditional antiepileptic drugs on course and outcome of status epilepticus.	2 7 30
606 605 604	Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs. 2020, 102, 106634 First add-on perampanel for focal-onset seizures: An open-label, prospective study. 2020, 141, 132-140 The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. 2020, 166, 107811 Influence of new versus traditional antiepileptic drugs on course and outcome of status epilepticus. 2020, 74, 20-25 From Standard of Care to Personalized (Art of) Medicine: Two Novel GABA-A Receptor B Subunit	2 7 30 2
606 605 604 603	Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs. 2020, 102, 106634 First add-on perampanel for focal-onset seizures: An open-label, prospective study. 2020, 141, 132-140 The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. 2020, 166, 107811 Influence of new versus traditional antiepileptic drugs on course and outcome of status epilepticus. 2020, 74, 20-25 From Standard of Care to Personalized (Art of) Medicine: Two Novel GABA-A Receptor B Subunit Mutations Associated With Epilepsy Syndromes. 2020, 20, 45-47 Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.	2 7 30 2

598	Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation. 2020 , 12, 135-147	1
597	Incremental burden of mental health conditions in adult patients with focal seizures. 2020 , 112, 107426	1
596	Impact of predictive, preventive and precision medicine strategies in epilepsy. 2020 , 16, 674-688	21
595	The Preoperative Evaluation of Drug-Resistant Epilepsy. 2020 , 112, 78-83	O
594	Patient satisfaction with information provided by epilepsy specialist nurses: Results of an online survey. 2020 , 112, 107273	1
593	New era of personalised epilepsy management. 2020 , 371, m3658	10
592	Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review. 2020 , 20, 1085-1098	6
591	Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy. 2020 ,	3
590	Drug-resistant epilepsy - time to target mechanisms. 2020 , 16, 595-596	7
589	Using ICD-10 codes to identify elective epilepsy monitoring unit admissions from administrative billing data: A validation study. 2020 , 111, 107194	2
588	Real-world experience with direct brain-responsive neurostimulation for focal onset seizures. 2020 , 61, 1749-1757	29
587	Misperceptions on the chance of seizure freedom with antiseizure medications after two failed trials. 2020 , 61, 1789-1790	6
586	COX-2/PGE axis regulates hippocampal BDNF/TrkB signaling via EP2 receptor after prolonged seizures. 2020 , 5, 418-431	15
585	Seizure-related injuries in inadequately treated epilepsy patients: A case-control study. 2020 , 83, 17-20	1
584	Cenobamate in focal seizures: a profile of its use. 2020 , 36, 327-334	О
583	Rediscovery of Rue for the treatment of epilepsy. 2020 , 167, 106434	
582	Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred vs inbred mice. 2020 , 61, 2022-2034	5
581	The patterns of response of 11 regimens for infantile spasms. 2020 , 10, 11509	1

(2020-2020)

580	Endosomal-lysosomal dysfunction in metabolic diseases and Alzheimer's disease. 2020 , 154, 303-324	1
579	Transcranial magnetic stimulation as a tool to understand genetic conditions associated with epilepsy. 2020 , 61, 1818-1839	2
578	Cross talk between drug-resistant epilepsy and the gut microbiome. 2020, 61, 2619-2628	17
577	Xenon Exerts Neuroprotective Effects on Kainic Acid-Induced Acute Generalized Seizures in Rats Increased Autophagy. 2020 , 14, 582872	2
576	Characteristics and treatment outcomes of newly diagnosed epilepsy in older people: A 30-year longitudinal cohort study. 2020 , 61, 2720-2728	4
575	Seizure-Induced Oxidative Stress in Status Epilepticus: Is Antioxidant Beneficial?. 2020 , 9,	14
574	The costs of epilepsy in Australia: A productivity-based analysis. 2020 , 95, e3221-e3231	9
573	Epilepsy syndromes, etiologies, and the use of next-generation sequencing in epilepsy presenting in the first 2 years of life: A population-based study. 2020 , 61, 2486-2499	6
572	Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis. 2020 , 34, 1105-1120	17
571	MicroRNAs and target genes in epileptogenesis. 2020 , 61, 2086-2096	4
570	The Natural History of Epilepsy. 2020 , 1-13	
569	Challenges in Identifying Medication-Resistant Epilepsy. 2020 , 14-19	
568	International League Against Epilepsy Definition of Medication-Resistant Epilepsy. 2020, 20-26	
567	The Economic Impact of Medication-Resistant Epilepsy. 2020 , 27-33	
566	Social Consequences of Medication-Resistant Epilepsy. 2020 , 34-38	
566 565	Social Consequences of Medication-Resistant Epilepsy. 2020 , 34-38 Mortality and Morbidity of Medication-Resistant Epilepsy. 2020 , 39-50	

562	Genetic Causes of Medication-Resistant Epilepsy. 2020 , 69-78	
561	Malformations of Cortical Development as Causes of Medication-Resistant Epilepsy. 2020 , 79-86	
560	Hippocampal Sclerosis as a Cause of Medication-Resistant Epilepsy. 2020 , 87-99	
559	Autoimmune Causes of Medication-Resistant Epilepsy. 2020 , 100-117	
558	Medication-Resistant Epilepsy Syndromes in Children. 2020 , 118-157	
557	Medication-Resistant Epilepsy in Adults. 2020 , 158-170	1
556	Approach to the Treatment of Medication-Resistant Epilepsy. 2020 , 171-178	
555	Pharmacotherapy for Medication-Resistant Epilepsy. 2020 , 179-186	2
554	Reproductive Health for Women with Medication-Resistant Epilepsy. 2020 , 187-197	
553	Resective Surgery for Medication-Resistant Epilepsy. 2020 , 198-209	
552	Ablative Surgery for Medication-Resistant Epilepsy. 2020 , 210-218	
551	Stimulation Treatment for Medication-Resistant Epilepsy. 2020 , 219-240	
550	Diet Therapy for Medication-Resistant Epilepsy. 2020 , 241-247	
549	Botanical Treatments for Medication-Resistant Epilepsy. 2020 , 248-255	
548	Psychiatric Comorbidities in Medication-Resistant Epilepsy. 2020 , 256-268	
547	Surgical decision-making among patients with uncontrolled epilepsy: "Making important decisions about my brain, which I happen to love". 2020 , 1742395320968622	1
546	Metabolic Control of Epilepsy: A Promising Therapeutic Target for Epilepsy. 2020 , 11, 592514	6
545	Prognostic Implications of Epilepsy Onset Age According to Relapse Pattern in Patients with Four-Year Remission. 2020 , 10,	O

544	Carbamazepine and me!. 2020 , 83, 249-250	О
543	Successful treatment of drug-resistant status epilepticus in an adult patient with Mowat-Wilson syndrome: A case report. 2020 , 14, 100410	2
542	The challenges of continued antiseizure medicine trials. 2020 , 61, 2613-2614	О
541	Evaluation of the Protective Effect of Ademetionine, Cytoflavin, and Dihydroquercetetine on Blood Enzymes Activity in Rats Treated with High Doses of Sodium Valproate. 2020 , 170, 211-214	
540	Levetiracetam for Benzodiazepine-Refractory Status Epilepticus. 2020 , 87, 489-490	
539	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. 2020 , 21, 325-335	8
538	Discovery of the First Vitamin K Analogue as a Potential Treatment of Pharmacoresistant Seizures. 2020 , 63, 5865-5878	6
537	Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. 2020 , 94, e2311-e2322	45
536	DEPDC5 haploinsufficiency drives increased mTORC1 signaling and abnormal morphology in human iPSC-derived cortical neurons. 2020 , 143, 104975	4
535	Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial. 2020 , 167, 106369	5
534	Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. 2020 , 72, 606-638	121
533	Revisiting the Impact of Neurodegenerative Proteins in Epilepsy: Focus on Alpha-Synuclein, Beta-Amyloid, and Tau. 2020 , 9,	4
532	Antidepressant effect of vagal nerve stimulation in epilepsy patients: a systematic review. 2020 , 41, 3075-308	848
531	Epilepsy: key experimental therapeutics in early clinical development. 2020 , 29, 373-383	18
530	Characterization and treatment of spontaneous recurrent seizures following nerve agent-induced status epilepticus in mice. 2020 , 162, 106320	5
529	Testing association of rare genetic variants with resistance to three common antiseizure medications. 2020 , 61, 657-666	9
528	Editorial: Ketogenic Diet in Epilepsy and Associated Comorbidities: Clinical Efficacy and Mechanisms. 2020 , 11, 66	1
527	Localizing the epileptogenic zone. 2020 , 33, 198-206	10

526	The ketogenic diet all grown up-Ketogenic diet therapies for adults. 2020 , 162, 106319	8
525	Forecasting cycles of seizure likelihood. 2020 , 61, 776-786	36
524	The treatment outcomes of epilepsy and its root causes in children attending at the University of Gondar teaching hospital: A retrospective cohort study, 2018. 2020 , 15, e0230187	5
523	In Vivo Imaging of Neuroinflammatory Targets in Treatment-Resistant Epilepsy. 2020 , 20, 5	8
522	Not your parents' ketogenic diet - Flexibility in 2020. 2020 , 162, 106307	3
521	Remarkably High Efficacy of Cenobamate in Adults With Focal-Onset Seizures: A Double-Blind, Randomized, Placebo-Controlled Trial. 2020 , 20, 85-87	14
520	The Role of Excitability and Network Structure in the Emergence of Focal and Generalized Seizures. 2020 , 11, 74	6
519	What has been the impact of new drug treatments on epilepsy?. 2020 , 33, 185-190	21
518	Epileptic: David B. 2020 , 20, 433	
517	Gene tests in adults with epilepsy and intellectual disability. 2020 , 16, 527-528	1
517 516	Gene tests in adults with epilepsy and intellectual disability. 2020, 16, 527-528 Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. 2020, 111, 107261	2
	Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. 2020 ,	
516	Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. 2020 , 111, 107261 -Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision	2
516 515	Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. 2020 , 111, 107261 -Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision Medicine. 2020 , 9, 252-257	2
516 515 514	Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. 2020, 111, 107261 -Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision Medicine. 2020, 9, 252-257 Proteins Alleviate Pentylenetetrazol-Induced Seizures in Zebrafish. 2020, 8, Proceedings of the 15th Antiepileptic Drug and Device Trials Meeting: State of the Science. 2020,	2 6 5
516 515 514 513	Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. 2020, 111, 107261 -Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision Medicine. 2020, 9, 252-257 Proteins Alleviate Pentylenetetrazol-Induced Seizures in Zebrafish. 2020, 8, Proceedings of the 15th Antiepileptic Drug and Device Trials Meeting: State of the Science. 2020, 111, 107189	2 6 5
516 515 514 513 512	Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. 2020, 111, 107261 -Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision Medicine. 2020, 9, 252-257 Proteins Alleviate Pentylenetetrazol-Induced Seizures in Zebrafish. 2020, 8, Proceedings of the 15th Antiepileptic Drug and Device Trials Meeting: State of the Science. 2020, 111, 107189 A Composite Sketch of Fast-Spiking Parvalbumin-Positive Neurons. 2020, 1, tgaa026	2 6 5 6

508	Sleep disruption is not observed with brain-responsive neurostimulation for epilepsy. 2020 , 5, 155-165	6
507	Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy. 2020 , 104, 106883	4
506	Hilbert Vibration Decomposition-based epileptic seizure prediction with neural network. 2020 , 119, 103665	14
505	Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects. 2020 , 9, 428-443	24
504	Somatosensory evoked fields predict response to vagus nerve stimulation. 2020 , 26, 102205	10
503	Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy. <i>JAMA</i> Neurology, 2020 , 77, 574-581	14
502	Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. 2020 , 16, 227-238	18
501	Mechanisms of action of currently used antiseizure drugs. 2020 , 168, 107966	102
500	Avoiding complacency when treating uncontrolled seizures: why and how?. 2020, 20, 227-235	2
499	Cardiometabolic risk and effectiveness of the modified Atkins Ketogenic Diet for adult patients with pharmacoresistant epilepsies in a middle-income country. 2020 , 160, 106280	5
499 498		2
	with pharmacoresistant epilepsies in a middle-income country. 2020 , 160, 106280	
498	with pharmacoresistant epilepsies in a middle-income country. 2020 , 160, 106280 Pediatric epilepsy. 2020 , 207-233 Effectiveness, retention, and safety of modified ketogenic diet in adults with epilepsy at a	2
498 497	with pharmacoresistant epilepsies in a middle-income country. 2020, 160, 106280 Pediatric epilepsy. 2020, 207-233 Effectiveness, retention, and safety of modified ketogenic diet in adults with epilepsy at a tertiary-care centre in the UK. 2020, 267, 1171-1178 Health-related quality of life and its determinants among ambulatory patients with epilepsy at	10
498 497 496	with pharmacoresistant epilepsies in a middle-income country. 2020, 160, 106280 Pediatric epilepsy. 2020, 207-233 Effectiveness, retention, and safety of modified ketogenic diet in adults with epilepsy at a tertiary-care centre in the UK. 2020, 267, 1171-1178 Health-related quality of life and its determinants among ambulatory patients with epilepsy at Ambo General Hospital, Ethiopia: Using WHOQOL-BREF. 2020, 15, e0227858 Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability.	2 10 6
498 497 496 495	Pediatric epilepsy. 2020, 207-233 Effectiveness, retention, and safety of modified ketogenic diet in adults with epilepsy at a tertiary-care centre in the UK. 2020, 267, 1171-1178 Health-related quality of life and its determinants among ambulatory patients with epilepsy at Ambo General Hospital, Ethiopia: Using WHOQOL-BREF. 2020, 15, e0227858 Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability. 2020, 24, 629-637	2 10 6
498 497 496 495 494	Pediatric epilepsy. 2020, 207-233 Effectiveness, retention, and safety of modified ketogenic diet in adults with epilepsy at a tertiary-care centre in the UK. 2020, 267, 1171-1178 Health-related quality of life and its determinants among ambulatory patients with epilepsy at Ambo General Hospital, Ethiopia: Using WHOQOL-BREF. 2020, 15, e0227858 Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability. 2020, 24, 629-637 Seizure freedom as an outcome in epilepsy treatment clinical trials. 2020, 142, 91-107 Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in	2 10 6 1 3

490	Position paper of a German interdisciplinary round table on future designs of trials on adjunctive treatment with antiseizure drugs. 2020 , 78, 53-56	1
489	Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy. 2021 , 121, 677-684	1
488	Cenobamate: A New Adjunctive Agent for Drug-Resistant Focal Onset Epilepsy. 2021 , 55, 318-329	6
487	Pharmacological treatment of focal epilepsy in adults: an evidence based approach. 2021 , 22, 317-323	3
486	Barriers to biomedical care for people with epilepsy in Uganda: A cross-sectional study. 2021 , 114, 107349	3
485	Is the mechanism of action of antiseizure drugs a key element in the choice of treatment?. 2021 , 35, 552-563	3
484	[Cenobamate-a´new perspective for epilepsy treatment]. 2021 , 92, 150-160	1
483	Continuing Burden of Refractory Epilepsy. 2021 , 55, 406-408	3
482	Post-ictal Generalized EEG Suppression is reduced by Enhancing Dorsal Raphe Serotonergic Neurotransmission. 2021 , 453, 206-221	7
481	Connectome biomarkers of drug-resistant epilepsy. 2021 , 62, 6-24	17
481 480	Connectome biomarkers of drug-resistant epilepsy. 2021 , 62, 6-24 Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?. 2021 , 62, 228-237	3
480	Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?. 2021 , 62, 228-237	3
480 479	Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?. 2021 , 62, 228-237 Surgery in intractable epilepsy-physicians' recommendations and patients' decisions. 2021 , 143, 421-429 Accuracy and Safety of Customized Stereotactic Fixtures for Stereoelectroencephalography in	3
480 479 478	Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?. 2021, 62, 228-237 Surgery in intractable epilepsy-physicians' recommendations and patients' decisions. 2021, 143, 421-429 Accuracy and Safety of Customized Stereotactic Fixtures for Stereoelectroencephalography in Pediatric Patients. 2021, 99, 17-24	3 1 2
480 479 478 477	Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?. 2021, 62, 228-237 Surgery in intractable epilepsy-physicians' recommendations and patients' decisions. 2021, 143, 421-429 Accuracy and Safety of Customized Stereotactic Fixtures for Stereoelectroencephalography in Pediatric Patients. 2021, 99, 17-24 Precision Medicine: Academic dreaming or clinical reality?. 2021, 62 Suppl 2, S78-S89	3 1 2
480 479 478 477 476	Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?. 2021, 62, 228-237 Surgery in intractable epilepsy-physicians' recommendations and patients' decisions. 2021, 143, 421-429 Accuracy and Safety of Customized Stereotactic Fixtures for Stereoelectroencephalography in Pediatric Patients. 2021, 99, 17-24 Precision Medicine: Academic dreaming or clinical reality?. 2021, 62 Suppl 2, S78-S89 Possible interplay between the theories of pharmacoresistant epilepsy. 2021, 53, 1998-2026	3 1 2

(2021-2021)

472	Unanticipated improvement in seizure control in drug-resistant epilepsy- real world observations. 2021 , 84, 60-65	1
471	Retention Rate and Efficacy of Perampanel with a Slow Titration Schedule in Adults. 2021 , 48, 105-111	3
470	The RNS System: brain-responsive neurostimulation for the treatment of epilepsy. 2021 , 18, 129-138	19
469	An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England. 2021 , 24, 1037-1051	1
468	Clinical evaluation of neuroinflammation in child-onset focal epilepsy: a translocator protein PET study. 2021 , 18, 8	4
467	Models for predicting treatment efficacy of antiepileptic drugs and prognosis of treatment withdrawal in epilepsy patients. 2021 , 3,	3
466	Medical Foods: Science, Regulation, and Practical Aspects. Summary of a Workshop. 2021 , 5, nzaa172	1
465	A Method to Induce Lamotrigine-Resistant Corneal Kindled Mice. 2021 , 181-199	
464	Predicting Epileptic SeizuresAn Update. 2021 , 345-360	1
463	Cenobamate tablets as a treatment for focal-onset seizures in adults. 2021 , 14, 161-172	2
463 462	Cenobamate tablets as a treatment for focal-onset seizures in adults. 2021 , 14, 161-172 Validating Coding for the Identification of Pediatric Treatment Resistant Epilepsy Patients. 2021 , 8, 232904	
462	Validating Coding for the Identification of Pediatric Treatment Resistant Epilepsy Patients. 2021 , 8, 232904	18X2 <u>1</u> 103780
462 461	Validating Coding for the Identification of Pediatric Treatment Resistant Epilepsy Patients. 2021 , 8, 232904 Non-invasive cortical stimulation: Transcranial direct current stimulation (tDCS). 2021 , 159, 1-22 Effect of Pre-Treatment with Acetaminophen on Hippocampal Oxidative, Inflammatory, and	18X2 <u>1</u> 103780
462 461 460	Validating Coding for the Identification of Pediatric Treatment Resistant Epilepsy Patients. 2021, 8, 232904 Non-invasive cortical stimulation: Transcranial direct current stimulation (tDCS). 2021, 159, 1-22 Effect of Pre-Treatment with Acetaminophen on Hippocampal Oxidative, Inflammatory, and Apoptotic Parameters in PTZ-Induced Acute Seizure Mice Model. 2021, 15, 79-85 Efficacy of levetiracetam in epilepsy and effect of concomitant drugs on the incidence of	18X2 <u>1</u> 103780
462 461 460 459	Validating Coding for the Identification of Pediatric Treatment Resistant Epilepsy Patients. 2021, 8, 232904 Non-invasive cortical stimulation: Transcranial direct current stimulation (tDCS). 2021, 159, 1-22 Effect of Pre-Treatment with Acetaminophen on Hippocampal Oxidative, Inflammatory, and Apoptotic Parameters in PTZ-Induced Acute Seizure Mice Model. 2021, 15, 79-85 Efficacy of levetiracetam in epilepsy and effect of concomitant drugs on the incidence of somnolence as an adverse effect. 2021, 13, 70-78	48X21103780 3
462 461 460 459 458	Validating Coding for the Identification of Pediatric Treatment Resistant Epilepsy Patients. 2021, 8, 232904 Non-invasive cortical stimulation: Transcranial direct current stimulation (tDCS). 2021, 159, 1-22 Effect of Pre-Treatment with Acetaminophen on Hippocampal Oxidative, Inflammatory, and Apoptotic Parameters in PTZ-Induced Acute Seizure Mice Model. 2021, 15, 79-85 Efficacy of levetiracetam in epilepsy and effect of concomitant drugs on the incidence of somnolence as an adverse effect. 2021, 13, 70-78 Closed-loop stimulation of the medial septum terminates epileptic seizures. 2021, 144, 885-908 [The efficacy and tolerability of extended release carbamazepine in adult patients with new-onset	3 12

454	The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results. 2021 , 62, 857-873	5
453	Changes in resting-state cerebral blood flow and its connectivity in patients with focal to bilateral tonic-clonic seizures. 2021 , 115, 107687	2
452	Long-term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy. 2021 , 62, 659-670	9
451	Cannabidiol in the Treatment of Epilepsy. 2021 , 41, 211-220	5
450	The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy. 2021 , 22, 171-182	3
449	Can Big Data guide prognosis and clinical decisions in epilepsy?. 2021 , 62 Suppl 2, S106-S115	1
448	The Impact of COVID-19 Lockdown on People With Epilepsy and Vagal Nerve Stimulation. 2021 , 12, 640581	5
447	Sublayer- and cell-type-specific neurodegenerative transcriptional trajectories in hippocampal sclerosis.	
446	Closing the Diagnostic Gap in Epilepsy: Recognizing More Than Just Motor Seizures. 2021 , 21, 173-174	1
445	Wenn Epilepsiechirurgie die personalisierte Therapie der Wahl ist: Muss Pharmakoresistenz wirklich immer zwingend belegt werden?. 2021 , 34, 197-201	
444	Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis. 2021 , 144, 58-66	1
443	Ambulatory care for epilepsy via telemedicine during the COVID-19 pandemic. 2021 , 116, 107740	7
442	Comparative 12-month retention rate, effectiveness and tolerability of perampanel when used as a first add-on or a late add-on treatment in patients with focal epilepsies: The COM-PER study. 2021 , 86, 109-115	3
441	Epilepsy Treatment Complacency in Patients, Caregivers, and Health Care Professionals. 2021 , 11, 377-384	
440	The Role of Phospholipase C in GABAergic Inhibition and Its Relevance to Epilepsy. 2021 , 22,	2
439	Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic. 2021 , 116, 107746	1
438	Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy. 2021 , 21, 1317-1332	8
437	Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment. 2021 , 116, 107796	4

436	Spatiotemporal Correlation of Epileptiform Activity and Gene Expression. 2021, 14, 643763	1
435	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. 2021 , 35, 265-281	7
434	DBS for refractory epilepsy: is closed-loop stimulation of the medial septum the way forward?. 2021 , 144, 702-705	
433	Bidirectional regulation of glial potassium buffering - glioprotection versus neuroprotection. 2021 , 10,	O
432	First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. 2021 , 62, 1119-1129	9
431	Synthesis, Anticonvulsant, and Antinociceptive Activity of New 3-(2-Chlorophenyl)- and 3-(3-Chlorophenyl)-2,5-dioxo-pyrrolidin-1-yl-acetamides. 2021 , 26,	3
430	Characterization of induction methods forDrosophilaseizure mutations.	
429	Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations. 2021 , 64, 3100-3114	10
428	Brain angiotensin system: a new promise in the management of epilepsy?. 2021, 135, 725-730	2
427	Transcranial direct current stimulation (tDCS) in the management of epilepsy: A systematic review. 2021 , 86, 85-95	11
426	Towards realizing the vision of precision medicine: AI based prediction of clinical drug response. 2021 , 144, 1738-1750	9
425	Pre-surgical Evaluation. 2021 , 345-365	
424	Two-Photon Imaging to Unravel the Pathomechanisms Associated with Epileptic Seizures: A Review. 2021 , 11, 2404	2
423	Microvascular changes associated with epilepsy: A narrative review. 2021 , 41, 2492-2509	2
422	Levetiracetam, perampanel, and the issue of aggression: A self-report study. 2021, 117, 107806	6
421	The psychosocial impact of COVID-19 within the first six months of the pandemic on youth with epilepsy and their caregivers. 2021 , 117, 107855	2
420	Facial memory ability and self-awareness in patients with temporal lobe epilepsy after anterior temporal lobectomy. 2021 , 16, e0248785	0
419	Understanding drug-resistant epilepsy. 2021 , 17, 59-61	

418	Characterizing the electrophysiological abnormalities in visually reviewed normal EEGs of drug-resistant focal epilepsy patients. 2021 , 3, fcab102	1
417	Response to first antiseizure medication in patients diagnosed with epilepsy. 2021 , 144, 67-75	2
416	Patient, caregiver, and healthcare professional perspectives on seizure control and treatment goals. 2021 , 117, 107816	3
415	Transcutaneous auricular vagus nerve stimulation induces stabilizing modifications in large-scale functional brain networks: towards understanding the effects of taVNS in subjects with epilepsy. 2021 , 11, 7906	6
414	Alzheimer's Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation. 2021 , 46, 1895-1912	4
413	Brivaracetam Retention Rate and Seizure Outcomes in Patients with Drug-Resistant Focal Epilepsy Included in the Medical Need Program in Belgium: A Real-World, Multicenter, Chart Review. 2021 , 8, 407-415	O
412	Pregabalin as adjunctive therapy in adult and pediatric patients with generalized tonic-clonic seizures: A randomized, placebo-controlled trial. 2021 , 6, 381-393	1
411	Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy. 2021 , 21, 1265-1273	4
410	Seizure Forecasting Using a Novel Sub-Scalp Ultra-Long Term EEG Monitoring System.	1
409	Surgical Outcomes and EEG Prognostic Factors After Stereotactic Laser Amygdalohippocampectomy for Mesial Temporal Lobe Epilepsy. 2021 , 12, 654668	1
408	Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States. 2021 , 118, 107927	1
407	Evaluation of Factors Impacting the Efficacy of Single or Combination Therapies of Valproic Acid, Carbamazepine, and Oxcarbazepine: A Longitudinal Observation Study. 2021 , 12, 641512	1
406	Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. 2021 , 6, 276-296	5
405	Reduction of Retinal Thickness Ipsilateral to Hippocampal Sclerosis in Epilepsy. 2021 , 12, 663559	
404	Forecasting seizure likelihood with wearable technology.	
403	Assessing the role of rare genetic variants in drug-resistant, non-lesional focal epilepsy. 2021 , 8, 1376-1387	3
402	Progress Toward Obtaining Seizure Freedom With New Medications in Older Adults. 2021 , 21, 267-269	
401	Cortical expression of IL1-DBcl-2, Caspase-3 and 9, SEMA-3a, NT-3 and P-glycoprotein as biological markers of intrinsic severity in drug-resistant temporal lobe epilepsy. 2021 , 1758, 147303	3

(2021-2021)

400	Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study. 2021 , 172, 106570	2
399	Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study. 2021 , 172, 106592	3
398	Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability. 2021 , 35, 609-618	10
397	Specialty Grand Challenge for Brain Disease Mechanisms. 2021 , 14, 689903	O
396	Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies. 2021 , 1-11	1
395	One step closer towards personalized epilepsy management. 2021 , 144, 1624-1626	1
394	Budget Impact Analysis of Treatment Flow Optimization in Epilepsy Patients: Estimating Potential Impacts with Increased Referral Rate to Specialized Care. 2021 , 8, 80-87	
393	Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment. 2021 , 97, e720-e727	O
392	What value can TSPO PET bring for epilepsy treatment?. 2021 , 1	2
391	Epilepsy and syphilis: A systematic review and meta-analysis. 2021 , 87, 483-490	1
390	Psychiatric disorders of the combination of levetiracetam either with lacosamide or perampanel: a retrospective cohort study. 2021 , 43, 1516-1522	O
389	Sublayer- and cell-type-specific neurodegenerative transcriptional trajectories in hippocampal sclerosis. 2021 , 35, 109229	2
388	The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. 2021, 12, 674483	11
387	Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis. 2021 , 38, 4082-4099	1
386	Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. 2021 , 12, 688386	2
385	Budget Impact Analysis of Treatment Flow Optimization in Epilepsy Patients: Estimating Potential Impacts with Increased Referral Rate to Specialized Care. 2021 , 8, 80-87	1
384	Epileptic Seizure Detection on an Ultra-Low-Power Embedded RISC-V Processor Using a Convolutional Neural Network. 2021 , 11,	2
383	The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. 2021 , 35, 935-963	11

382	Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes. 2021 , 119, 107935	1
381	Dietary medium chain triglycerides for management of epilepsy: New data from human, dog, and rodent studies. 2021 , 62, 1790-1806	6
380	Optimal Use of Perampanel in Asian Patients with Epilepsy: Expert Opinion. 2021 , 17, 739-746	O
379	Forecasting Seizure Likelihood With Wearable Technology. 2021 , 12, 704060	7
378	Characterization of Seizure Induction Methods in. 2021 , 8,	1
377	Etiology-specific response to antiseizure medication in focal epilepsy. 2021 , 62, 2133-2141	1
376	Practical considerations of dietary therapies for epilepsy in adults. 2021 , 3,	O
375	Changes in epilepsy causes of death: A US population study. 2021 , 144, 478-485	2
374	Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies. 2021, 17, 2229-2242	9
373	Antiseizure effects of the cannabinoids in the amygdala-kindling model. 2021 , 62, 2274-2282	O
372	Extrapial Hippocampal Resection in Anterior Temporal Lobectomy: Technical Description and Clinical Outcomes in a 62-Patient Case Series. 2021 , 21, 312-323	
371	Synthesis, in silico, in vitro and in vivo evaluations of isatin aroylhydrazones as highly potent anticonvulsant agents. 2021 , 112, 104943	6
370	Potential for improved retention rate by personalized antiseizure medication selection: A register-based analysis. 2021 , 62, 2123-2132	O
369	Chronic limbic epilepsy models for therapy discovery: Protocols to improve efficiency. 2021 , 62, 2252-2262	
368	Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?. 2021 , 18, 1515-1523	O
367	Making the Invisible Visible: Advanced Neuroimaging Techniques in Focal Epilepsy. 2021 , 15, 699176	3
366	The Medial Septum as a Potential Target for Treating Brain Disorders Associated With Oscillopathies. 2021 , 15, 701080	3
365	High-Frequency Oscillations on Interictal Epileptiform Discharges in Routinely Acquired Scalp EEG: Can It Be Used as a Prognostic Marker?. 2021 , 15, 709836	О

(2021-2021)

364	Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy. 2021 , 10,	
363	Efficacy and safety of using vagus nerve stimulation in patients with pharmacoresistant epilepsy in the Russian Federation: a multi-center retrospective observational program. 2021 , 13, 106-122	1
362	Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up. 2021 , 121, 108069	2
361	Short- and Long-Term Response of Vagus Nerve Stimulation Therapy in Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis. 2021 ,	2
360	Severity and disability related to epilepsy from the perspective of patients and physicians: A cross-cultural adaptation of the GASE and GAD scales. 2021 , 90, 93-98	0
359	Update on the Neuroimaging and Electroencephalographic Biomarkers of Epileptogenesis: A Literature Review. 2021 , 12, 738658	1
358	A web-based algorithm to rapidly classify seizures for the purpose of drug selection. 2021 , 62, 2474-2484	2
357	A review of a diazepam nasal spray for the treatment of acute seizure clusters and prolonged seizures. 2021 , 21, 1207-1212	O
356	Gut-microbiota-directed strategies to treat epilepsy: clinical and experimental evidence. 2021 , 90, 80-92	4
355	Change in the Frequency of Seizure Attacks and Associated Factors Among Adult Epilepsy Patients at Amanuel Mental Specialized Hospital (AMSH): A Generalized Linear Mixed Model (GLMM). 2021 , 17, 2529-2538	Ο
354	Novel Electrode Architecture for Subgaleal Electroencephalography: A Feasibility Study.	
353	Perampanel treatment in highly drug-resistant epilepsies including nonsurgical candidates and failed surgery. 2021 , 121, 108073	O
352	MicroRNA-221-3p Suppresses the Microglia Activation and Seizures by Inhibiting of HIF-1⊞n Valproic Acid-Resistant Epilepsy. 2021 , 12, 714556	2
351	The relation of etiology based on the 2017 ILAE classification to the effectiveness of the ketogenic diet in drug-resistant epilepsy in childhood. 2021 , 62, 2814-2825	
350	Seizure Forecasting Using a Novel Sub-Scalp Ultra-Long Term EEG Monitoring System. 2021 , 12, 713794	5
349	Epilepsy and Deep Brain Stimulation of Anterior Thalamic Nucleus. 2021 , 13, e18199	1
348	[Imaging in the presurgical evaluation of epilepsy]. 2021 , 1	0
347	How much can medical management alone improve the outcome of adult drug-resistant epilepsy? An exploratory study on possibilities and limitations of combining multiple therapeutic actions. 2021 , 122, 108065	

346	4-Aminopyridine is a promising treatment option for patients with gain-of-function -encephalopathy. 2021 , 13, eaaz4957	11
345	Cutting edge approaches to detecting brain mosaicism associated with common focal epilepsies: implications for diagnosis and potential therapies. 2021 , 21, 1309-1316	О
344	Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development. 2021 , 193, 114786	5
343	What is the effect of delays in access to specialist epilepsy care on patient outcomes? A systematic review and meta-analysis. 2021 , 122, 108192	O
342	Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies. 2021 ,	3
341	Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). 2021 , 35, 1289-1301	7
340	Healthcare professionals' knowledge, attitude, and perception of epilepsy surgery: A systematic review. 2021 , 122, 108199	5
339	Brain Stimulation Treatments in Epilepsy: Basic Mechanisms and Clinical Advances. 2021 ,	O
338	Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA). 2021 , 122, 108222	1
337	Fructose 1,6-bisphosphate is anticonvulsant and improves oxidative glucose metabolism within the hippocampus and liver in the chronic pilocarpine mouse epilepsy model. 2021 , 122, 108223	O
336	Epilepsy Surgery: Special Circumstances. 2021 , 39, 100921	
335	Intraoperative microseizure detection using a high-density micro-electrocorticography electrode array.	O
334	Individuals who develop drug-resistant epilepsy within a year after initial diagnosis have higher burden of mental and physical diseases one-year prior to epilepsy diagnosis as compared to those whose seizures were controlled during the same interval. 2021 , 123, 108243	О
333	Difficulties obtaining private insurance reported by persons with epilepsy in Korea. 2021 , 123, 108266	
332	Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials. 2021 , 91, 339-345	0
331	The prognosis of epilepsy patients with CACNA1H missense variants: A longitudinal cohort study. 2021 , 91, 52-59	2
330	Can machine learning improve randomized clinical trial analysis?. 2021 , 91, 499-502	О
329	Machine learning models for decision support in epilepsy management: A critical review. 2021 , 123, 108273	2

328 Novel approaches in pharmacological treatment of epilepsy. **2021**, 22, 176-181

327	A ketogenic diet protects DBA/1 and Scn1a mice against seizure-induced respiratory arrest independent of ketosis. 2021 , 124, 108334	O
326	Transcutaneous vagus nerve stimulation in the treatment of drug-resistant epilepsy. 2021 , 235, 102840	4
325	Long-term response and response patterns to antiepileptic drugs in patients with newly diagnosed epilepsy. 2021 , 124, 108309	
324	Synthesizing Multi-tracer PET Images for Alzheimer Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial Network. 2021 , 34-43	1
323	Neuromodulation in Drug Resistant Epilepsy. 2021 , 12, 1070-1080	8
322	Epilepsy. 2021 , 599-605	
321	Antiepileptic drugs for acute encephalitic patients presented with seizure. 2020 , 164, 106347	1
320	Predictors of drug-resistance in epilepsy with auditory features. 2020 , 164, 106353	1
319	Trends in hospitalization and readmission for pediatric epilepsy and underutilization of epilepsy surgery in the United States. 2020 , 80, 263-269	8
318	Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach. 2020 , 2, fcaa183	3
317	Utilization of MEG Among the US Epilepsy Centers: A Survey-Based Appraisal. 2020 , 37, 599-605	11
316	Forecasting Cycles of Seizure Likelihood.	4
315	Antiepileptic Drug Therapy in Patients with Drug-Resistant Epilepsy. 2019 , 9, 14-26	21
314	Current trends in epileptology: priorities, challenges, tasks and solutions. 2020 , 11, 395-406	7
313	Microglial contributions to aberrant neurogenesis and pathophysiology of epilepsy. 2020 , 7, 234-247	4
312	How to Find Candidate Drug-targets for Antiepileptogenic Therapy?. 2020 , 18, 624-635	2
311	Recent advances in the neurosurgical treatment of pediatric epilepsy: JNSPG 75th Anniversary Invited Review Article. 2019 , 23, 411-421	15

310	The Present and Future of Vagus Nerve Stimulation. 2019 , 62, 344-352	9
309	Effects of levetiracetam and lacosamide on therapeutic efficacy and neural function in patients with epilepsy. 2020 , 20, 3687-3694	1
308	Ictal asystole: a diagnostic and management conundrum. 2019 , 49, 128-131	4
307	Medical Cannabis in Children. 2020 , 11,	5
306	Markers of Neuroinflammation and Apoptosis in the Temporal Lobe of Patients with Drug-Resistant Epilepsy. 2021 , 57, 1040-1049	2
305	Metabolic´network îs ´related´to ´surgical´outcome în ´temporal lobe´epilepsy´with´hippocampal´sclerosis: ´A´bra 2021 ,	in FDG-PE
304	Neuromodulation in epilepsy: state-of-the-art approved therapies. 2021 , 20, 1038-1047	12
303	Markov modelling of treatment response in a 30-year cohort study of newly diagnosed epilepsy. 2021 ,	O
302	Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non-Japanese. 2021 ,	1
301	Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications. 2021 , 62, 3016-3028	6
300	Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy. 2021 , 12, 730257	4
299	G-alpha interacting protein interacting protein, C terminus 1 regulates epileptogenesis by increasing the expression of metabotropic glutamate receptor 7. 2021 ,	1
298	Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study. 2021 , 62, 3005-3015	4
297	Machine learning for brain age prediction: Introduction to methods and clinical applications. 2021 , 72, 103600	3
296	Recommendations of the Polish Society of Epileptology for the treatment of epileptic seizure in adult patients in Poland: an update. 2019 , 27, 9-16	2
295	Epilepsy Surgery for the Child with Cerebral Palsy. 2019 , 1-14	
294	Pyridox(am)ine 5Ephosphate oxidase deficiency induces seizures in Drosophila melanogaster.	
293	Pathogenesis of drug resistant epilepsy. 2019 , 11, 79-87	0

292 Quantification and selection of ictogenic zones in epilepsy surgery.

291	Konzept Pharmakoresistenz. 2020 , 471-477	
290	Post-ictal generalized EEG suppression and seizure-induced mortality are reduced by enhancing dorsal raphe serotonergic neurotransmission.	0
289	Index. 2020 , 269-274	
288	Changing characteristics of epilepsy interventional clinical trials over the last decade: Clinicaltrials.Gov registry. 2020 , 164, 106350	
287	Medication-Resistant Epilepsy: Diagnosis and Treatment. 2020 ,	
286	Bidirectional regulation of glial potassium buffering: glioprotection versus neuroprotection.	
285	Envisioning the role of inwardly rectifying potassium (Kir) channel in epilepsy. 2021,	1
284	Application of transformers for predicting epilepsy treatment response. 2021,	
283	Treatment Outcome and Risk Factors of Adult Newly Diagnosed Epilepsy: A Prospective Hospital-Based Study in Northeast China. 2021 , 12, 747958	Ο
282	Analysis of trends and factors determining initial antiseizure medication choice for epilepsy in Taiwan. 2021 , 93, 145-153	0
281	Tolerability of antiseizure medicines using Lithuanian version of the Liverpool Adverse Events Profile. 2021 , 124, 108371	1
280	Technological Challenges in the Development of Optogenetic Closed-Loop Therapy Approaches in Epilepsy and Related Network Disorders of the Brain. 2020 , 12,	3
279	Cenobamate for the Treatment of Focal Seizures. 2020 , 16, 87	2
278	Surgery for epilepsy. 2020 , 443-456	
277	Epilepsy Surgery for the Child with Cerebral Palsy. 2020 , 469-482	
276	Effectiveness at 24 Months of Single-Source Generic Carbamazepine, Lamotrigine, or Levetiracetam in Newly Diagnosed Focal Epilepsy. 2020 , 25, 1-3	
275	Epilepsy: Clinical, Epidemiological, and Therapeutical Aspects. 2020 , 13-18	

274 Monotherapie. **2020**, 457-463

273	Antiepileptika. 2020 , 431-456	
272	Fast oscillations >40Hz localize the epileptogenic zone: an electrical source imaging study using high-density electroencephalography.	
271	Closed-loop stimulation of the medial septum terminates epileptic seizures.	O
270	TPPU Pre-Treatment Rescues Dendritic Spine Loss and Alleviates Depressive Behaviours during the Latent Period in the Lithium Chloride-Pilocarpine-Induced Status Epilepticus Rat Model. 2021 , 11,	2
269	Analysis and Construction of a Molecular Diagnosis Model of Drug-Resistant Epilepsy Based on Bioinformatics. 2021 , 8, 683032	O
268	Moving the Research Forward: The Best of British Biology Using the Tractable Model System. 2021 , 10,	O
267	A retrospective, real-world experience of perampanel monotherapy in patient with first new onset focal seizure: A Thailand experience. 2021 ,	3
266	Application of transformers for predicting epilepsy treatment response.	1
265	Evaluation of the direct costs of epilepsy in a sample of Egyptian patients following up in Ain Shams University Hospital. 2020 , 56,	O
264	Presentation_1.pdf. 2018 ,	1
263	Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder. 2020 , 20, 146	
262	Using common genetic variants to find drugs for common epilepsies 2021 , 3, fcab287	O
261	Prescription patterns and dosages of antiepileptic drugs in prevalent patients with epilepsy in Taiwan: A nationwide retrospective cross-sectional study. 2021 , 126, 108450	1
260	Polypharmacy composition and patient- and provider-related variation in patients with epilepsy. 2021 , 126, 108428	O
259	Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations. 2021,	O
258	Pharmacoresponsiveness of spontaneous recurrent seizures and the comorbid sleep disorder of epileptic Kcna1-null mice. 2021 , 913, 174656	O
257	Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults. 2021 , 17, 3447-3457	2

256	The control of treated generalized and focal epilepsies during pregnancy. 2021 , 125, 108406	O
255	Drug Resistant Epilepsy and the hypothesis of intrinsic severity: What about the High-Frequency Oscillations?. 2021 ,	2
254	Can we predict anti-seizure medication response in focal epilepsy using machine learning?. 2021 , 211, 107037	
253	Seizure outcomes in people with drug-resistant focal epilepsy evaluated for surgery but do not proceed. 2021 , 178, 106822	1
252	BICS01 Mediates Reversible Anti-seizure Effects in Brain Slice Models of Epilepsy 2021 , 12, 791608	
251	Gut Microbiome Distinguishes Patients With Epilepsy From Healthy Individuals 2021 , 12, 696632	1
250	Novel Electrode Architecture for Subgaleal Electroencephalography: A Feasibility Study.	O
249	Attitudes and beliefs of medicine and social work students about medical cannabis use for epilepsy 2022 , 127, 108522	O
248	Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder. 2020 , 20, 146	
247	Noninvasive disconnection of targeted neuronal circuitry sparing axons of passage and nonneuronal cells. 2021 , 1-11	
246	Expression Profile of miRs in Mesial Temporal Lobe Epilepsy: Systematic Review 2022, 23,	1
245	Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis 2022 , 82, 199	4
244	Pyridoxine or pyridoxal-5-phosphate treatment for seizures in glycosylphosphatidylinositol deficiency: A cohort study 2022 ,	1
243	Changes in Pre- and Postsurgery for Drug Resistant Epilepsy: Cognition and Sleep 2022 , 2022, 9971780	O
242	Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis 2022 , 1	O
241	Synthetic Approaches toward the Synthesis of Brivaracetam: An Antiepileptic Drug 2022 , 7, 2486-2503	4
240	Genetic Analysis of Sodium Channel Genes in Pediatric Epilepsy Patients of Pakistan 2022 , 2022, 1168703	
239	Minimum standards for inpatient long-term video-EEG monitoring: A clinical practice guideline of the international league against epilepsy and international federation of clinical neurophysiology 2021 ,	4

238	The efficacy and safety of adjunctive Perampanel for the treatment of refractory focal-onset seizures in patients with epilepsy:A meta-analysis 2021 ,	0
237	Electrocorticographic and electrocardiographic evaluation of lacosamide in a penicillin-induced status epilepticus model 2022 , 180, 106866	Ο
236	The importance of drug titration in the management of patients with epilepsy 2022, 128, 108517	1
235	Anticonvulsant Agents: Beginning, Maintenance, Pharmacoresistance, Duration of Therapy, and Withdrawal: Adults. 2022 , 1-10	
234	Fluctuations in EEG band power at subject-specific timescales over minutes to days explain changes in seizure evolutions 2022 ,	О
233	Patient-Reported Outcome Measures in Adult Patients Diagnosed with Epilepsy Being Treated with Perampanel 2022 , 13, 39-52	
232	Definition of drug-resistant epilepsy: A reappraisal based on epilepsy types 2022,	
231	Epileptic discharges initiate from brain areas with elevated accumulation of Hamino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors 2022 , 4, fcac023	O
230	Lesional resective epilepsy surgery in childhood: Comparison of two decades and long-term seizure outcome from a single center 2022 , 181, 106882	O
229	Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications 2022 , 96, 86-93	O
228	Norwegian population-based study of long-term effects, safety, and predictors of response of vagus nerve stimulation treatment in drug-resistant epilepsy: The NORPulse study 2021 ,	1
227	Trends in Prescribing of Antiseizure Medications in South Korea: Real-World Evidence for Treated Patients With Epilepsy 2022 , 18, 179-193	O
226	Childhood Seizures. 2022 ,	
225	DUAL DEVICE NEUROMODULATION IN EPILEPSY 2022,	1
224	Brainstem Associated Somatosensory Evoked Potentials and Response to Vagus Nerve Stimulation: An Investigation of the Vagus Afferent Network 2021 , 12, 768539	
223	Parvalbumin Role in Epilepsy and Psychiatric Comorbidities: From Mechanism to Intervention 2022 , 16, 765324	O
222	Gut microbiome in neuropsychiatric disorders 2022 , 80, 192-207	О
221	Utility of 18F-fluorodeoxyglucose positron emission tomography in presurgical evaluation of patients with epilepsy: A multicenter study 2022 ,	O

220	Potential role of regulatory DNA variants in modifying the risk of severe cutaneous reactions induced by aromatic anti-seizure medications 2022 ,	0
219	Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy 2022 ,	O
218	Developing a Conceptual Disease Model of Patient Experiences and Identifying Patient-Reported Clinical Outcome Assessments for Use in Trials of Treatments for Focal Onset Seizures 2022 , 18, 611-631	
217	Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective 2022 , 10, 364	O
216	Amino Acids in the Treatment of Neurologic Disorders. 2022 , 466-474	
215	A Complex Systems View on the Current Hypotheses of Epilepsy Pharmacoresistance 2022,	
214	Light, Kindling, Action! Brain-wide Circuit Changes After Optogenetic Hippocampal Kindling Revealed by Functional Magnetic Resonance Imaging. 153575972210834	0
213	A novel epigenetic marker, Ten-eleven translocation family member 2 (TET2), is identified in the intractable epileptic brain and regulates ATP binding cassette subfamily B member 1 (ABCB1) in the blood-brain barrier 2022 , 13, 6638-6649	1
212	The metabolic basis of epilepsy 2022 ,	Ο
211	Multimodal Quality of Life Assessment in Post-9/11 Veterans With Epilepsy: Impact of Drug Resistance, Traumatic Brain Injury, and Comorbidity 2022 ,	Ο
210	Assessing and Intervening with Children with Seizure Disorders. 2022 , 359-371	
209	Neural Sources of Vagus Nerve Stimulation-Induced Slow Cortical Potentials 2022,	
208	Pathophysiological Mechanisms Underlying the Etiologies of Seizures and Epilepsy.	
207	Antiseizure Medications for Adults With Epilepsy: A Review 2022 , 327, 1269-1281	4
206	Approach to the Medical Treatment of Epilepsy 2022 , 28, 483-499	
205	Surgical Treatments for Epilepsy 2022 , 28, 536-558	
204	MicroRNA inhibition using antimiRs in acute human brain tissue sections.	
203	A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam 2022,	1

202	Big data analysis of ASM retention rates and expert ASM algorithm: a comparative study 2022,	О
201	Rational therapy with lamotrigine or levetiracetam: Which one to select?. 2022 , 99, 49-52	
200	Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience 2022 , 130, 108671	
199	Canadian epilepsy priority-setting partnership: Toward a new national research agenda 2022, 130, 108673	
198	Enhancing patients' experiences of living with epilepsy. 2021,	
197	Vagus nerve stimulation therapy in people with drug-resistant epilepsy (CORE-VNS): rationale and design of a real-world post-market comprehensive outcomes registry 2021 , 3, e000218	
196	Epilepsy Centers in the US: The Times They Are A-Changing. 2021,	
195	Neuroinflammation in EpilepsyDiagnostics and Therapeutic Perspectives. 2022, 8, 31-35	О
194	P.0054 The braindrugs-epilepsy cohort - precision medicine in the treatment of epilepsy. 2021 , 53, S39-S40	
193	Quality of life study for caregivers of people with uncontrolled focal-onset seizures 2022 , 25, 66-76	O
192	Minimum standards for inpatient long-term video-electroencephalographic monitoring: A clinical practice guideline of the International League Against Epilepsy and International Federation of Clinical Neurophysiology 2021 ,	2
191	Use of Interval Therapy with Benzodiazepines to Prevent Seizure Recurrence in Stressful Situations. 2022 , 12, 512	
190	Glucose-PEG2000-DSPE modified carbamazepine nano system alleviated cell apoptosis and oxidative stress in epilepsy 2022 , 1-13	
189	Prescription patterns among people with epilepsy 2022 , 130, 108690	
188	Table_1.DOCX. 2019 ,	
187	Table_2.DOCX. 2019 ,	
186	Table_3.DOCX. 2019 ,	
185	Table_1.DOCX. 2019 ,	_

184	Image_1.tif. 2020 ,	
183	Data_Sheet_1.PDF. 2020 ,	
182	Image_1.TIF. 2019 ,	
181	First Food and Drug Administration Cleared Thin-Film Electrode for Intracranial Stimulation, Recording, and Monitoring of Brain Activity-Part 1: Biocompatibility Testing 2022 , 16, 876877	1
180	Clinical Implementation of Ketogenic Diet in Children with Drug-Resistant Epilepsy: Advantages, Disadvantages, and Difficulties. 2022 ,	2
179	Reappraisal of the Medical Research Council Antiepileptic Drug Withdrawal Study: contamination-adjusted and dose-response re-analysis 2022 ,	O
178	Personalized tDCS for Focal Epilepsy Narrative Review: A Data-Driven Workflow Based on Imaging and EEG Data. 2022 , 12, 610	
177	Factors Predicting Outcome After Intracranial EEG Evaluation in Patients With Medically Refractory Epilepsy 2022 ,	1
176	Epilepsien. 2021 , 23-34	
175	Current Principles in the Management of Drug-Resistant Epilepsy 2022,	0
175 174	Current Principles in the Management of Drug-Resistant Epilepsy 2022, Measuring Real-Time Medication Effects From Electroencephalography 2022,	0
174	Measuring Real-Time Medication Effects From Electroencephalography 2022, Magnetic resonance imaging findings in children with intractable epilepsy compared to children	
174	Measuring Real-Time Medication Effects From Electroencephalography 2022, Magnetic resonance imaging findings in children with intractable epilepsy compared to children with medical responsive epilepsy 2022, 16, 53-61 Computational attributes of protein kinase-C gamma C2-domain & Samp; virtual screening for small	0
174 173 172	Measuring Real-Time Medication Effects From Electroencephalography 2022, Magnetic resonance imaging findings in children with intractable epilepsy compared to children with medical responsive epilepsy 2022, 16, 53-61 Computational attributes of protein kinase-C gamma C2-domain & Samp; virtual screening for small molecules: elucidation from meta-dynamics simulations & Samp; free-energy calculations. 1-12	0
174 173 172	Measuring Real-Time Medication Effects From Electroencephalography 2022, Magnetic resonance imaging findings in children with intractable epilepsy compared to children with medical responsive epilepsy 2022, 16, 53-61 Computational attributes of protein kinase-C gamma C2-domain & Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy. Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy.	0
174 173 172 171 170	Measuring Real-Time Medication Effects From Electroencephalography 2022, Magnetic resonance imaging findings in children with intractable epilepsy compared to children with medical responsive epilepsy 2022, 16, 53-61 Computational attributes of protein kinase-C gamma C2-domain & Disease-ening for small molecules: elucidation from meta-dynamics simulations & Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy. Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine. 2022, 13, Clinical prediction models for treatment outcome in newly-diagnosed epilepsy: Protocol for a	0

166	The Effectiveness of Antiepileptic Drug Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study. 10.1212/WNL.000000000000000000000000000000000000	O
165	Onset of efficacy and adverse events during Cenobamate titration period.	O
164	Transcutaneous Auricular Vagus Nerve Stimulation Differently Modifies Functional Brain Networks of Subjects With Different Epilepsy Types. 16,	0
163	Prophylactic administration of cannabidiol reduces microglial inflammatory response to kainate-induced seizures and neurogenesis. 2022 ,	O
162	Genome-wide meta-analysis of over 29,000 people with epilepsy reveals 26 loci and subtype-specific genetic architecture.	O
161	The impact of transcranial magnetic stimulation (TMS) on seizure course in people with and without epilepsy. 2022 ,	O
160	Precision medicine for genetic epilepsy on the horizon: recent advances, present challenges and suggestions for continued progress.	1
159	Neurosurgery in canine epilepsy. 2022 , 105852	O
158	Neue Entwicklungen in der antikonvulsiven Therapie bei Menschen mit Intelligenzminderung.	
157	Long-Term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures. 10.1212/WNL.0000000000200792	O
156	Seizure remission rates remain low in a resource-limited country, a multicentre comparison study in Malaysia. 2022 , 102, 60-64	
155	Impact of high-density EEG in presurgical evaluation for refractory epilepsy patients. 2022 , 219, 107336	
154	Automatic Detection of Adverse Drug Reactions from Online Health Forums. 2022,	
153	New evidence in adjunctive treatment of focal-onset seizures in adults: a critical appraisal. 2022 , 9, 14-19	O
152	TRPC channels as emerging targets for seizure disorders. 2022 ,	2
151	Pregabalin Add-On vs. Dose Increase in Levetiracetam Add-On Treatment: A Real-Life Trial in Dogs With Drug-Resistant Epilepsy. 9,	O
150	Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy. 2022 , 5, e2220189	1
149	Responsive Thalamic Neurostimulation: A Systematic Review of a Promising Approach for Refractory Epilepsy. 16,	O

148	Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach.	
147	The Seizure-Associated Genes Across Species (SAGAS) database offers insights into epilepsy genes, pathways and treatments.	
146	Timing of referral to evaluate for epilepsy surgery: Expert Consensus Recommendations from the Surgical Therapies Commission of the International League Against Epilepsy.	4
145	Zebrafish Is a Powerful Tool for Precision Medicine Approaches to Neurological Disorders. 15,	1
144	Personalised treatment for epilepsy: gender-specific comorbid emotional disturbances in drug-resistant epilepsy in neurosurgical patients. 2022 , 2, 63-72	
143	Cannabidiol and epilepsy in Brazil: a current review. 2022 , 80, 182-192	
142	Functionalized PEG-PLA nanoparticles for brain targeted delivery of ketoconazole contribute to Pregnane X receptor overexpressing in drug-resistant epilepsy. 2022 , 107000	
141	The role of sleep state and time of day in modulating breathing in epilepsy: implications for sudden unexpected death in epilepsy. 16,	0
140	The Prevention and Reversal of a Phenytoin-Resistant Model by N-acetylcysteine Therapy Involves the Nrf2/P-Glycoprotein Pathway at the Blood ${f B}$ rain Barrier.	
139	Centromedian thalamic neuromodulation for the treatment of idiopathic generalized epilepsy. 16,	1
138	Vagusnervstimulation bei Menschen mit Epilepsie und geistiger Behinderung. 2022 , 35, 217-220	
137	Best-worst scaling preferences among patients with well-controlled epilepsy: novel questionnaire development.	
136	The decreased connectivity in middle temporal gyrus can be used as a potential neuroimaging biomarker for left temporal lobe epilepsy. 13,	О
135	Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo.	2
134	The burden of epilepsy and unmet need in people with focal seizures.	1
133	Anti-seizure efficacy and retention rate of carbamazepine is highly variable in randomized controlled trials: a meta-analysis.	
132	Health Disparities in Pediatric Epilepsy: Methods and Lessons Learned.	
131	Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain. 1-10	O

130	Incidence of mental health conditions by seizure control among adults with epilepsy in the United States. 2022 , 134, 108865	O
129	Correlates of Caregiving Burden among Bedouin-Muslim Mothers of Children Diagnosed with Epilepsy. 2022 , 19, 11595	O
128	Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: Adjunctive cenobamate dose and seizure reduction by baseline seizure frequency. 2022 , 186, 107014	0
127	Differences in elective epilepsy monitoring unit admission rates by race/ethnicity and primary payer in New Jersey. 2022 , 136, 108923	O
126	The development of antiseizure medications. Commentary on The development of antiepileptic drugs by J.W.A. Meijer, H. Meinardi, and C.D. Binnie. 2023 , 241-247	0
125	Safety and efficacy of clonazepam in the treatment of juvenile myoclonic epilepsy: A meta-analysis. 2022 , 14, 126	O
124	Epilepsy Surgery in the Era with New Antiepileptic Drugs: Introduction of Neuromodulation Surgery in Epilepsy. 2022 , 31, 440-447	0
123	Treatment outcome and associated factors among epileptic patients at ambulatory clinic of Mettu Karl Comprehensive Specialized Hospital: A cross-sectional study. 2022 , 10, 205031212211251	О
122	Polypharmacology in Clinical Applications: Neurological Polypharmacology. 2022 , 231-269	0
121	Multidimensional Early Prediction Score for Drug-Resistant Epilepsy. 2022 , 18, 553	О
120	Sudden unexpected death in epilepsy: Respiratory mechanisms. 2022, 153-176	0
119	Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy.	1
118	Development and validation of a nomogram for the early prediction of drug resistance in children with epilepsy. 10,	0
117	Choosing the Best Antiseizure MedicationCan Artificial Intelligence Help?.	O
116	Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy.	0
115	Felbamate for pediatric epilepsyEhould we keep on using it as the last resort?. 13,	O
114	Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: Results from two double-blind, randomized, placebo-controlled trials.	O
113	Telemedicine and Epilepsy Care. 2022 ,	О

112	Connectome the Dots for Presurgical Predictions. 153575972211252	0
111	Chronobiology of epilepsy and sudden unexpected death in epilepsy. 16,	0
110	Current and future pharmacotherapy options for drug-resistant epilepsy. 1-12	0
109	Antiseizure medications (antiepileptic drugs) in adults: starting, monitoring and stopping.	0
108	Potential new roles for glycogen in epilepsy.	0
107	Incidence of and predictors for antiseizure medication gaps in Medicare beneficiaries with epilepsy: a retrospective cohort study. 2022 , 22,	O
106	Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach.	0
105	Early cost-utility analysis of genetically-guided therapy for patients with drug-resistant epilepsy.	O
104	Psychiatric symptoms and comorbidities in patients with drug-resistant epilepsy in presurgical assessment prospective explorative single center study. 13,	0
103	Paediatric epilepsy surgery: Techniques and outcomes.	O
102	Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. 2022 , 114237	1
101	Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study. 2022 , 136, 108937	O
100	Development and Validation of a UHPLCMS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples. 2022 , 27, 7325	0
99	GDNF Increases Inhibitory Synaptic Drive on Principal Neurons in the Hippocampus via Activation of the Ret Pathway. 2022 , 23, 13190	O
98	Sudden unexpected death in epilepsy: Pathogenesis, Risk Factors, and Prevention.	0
97	Actigraphic Correlates of Neuropsychiatric Disability in Adult Patients with Focal Epilepsy.	0
96	Anti-seizure medications and quality of life in person with epilepsy. 2022, 8, e11073	1
95	Association Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension.	1

94	Gut microbiota manipulation as an epilepsy treatment. 2022 , 174, 105897	О
93	Machine learning and statistic analysis to predict drug treatment outcome in pediatric epilepsy patients with tuberous sclerosis complex. 2022 , 188, 107040	1
92	Cognitive and behavioral effects of the anti-epileptic drug cenobamate (YKP3089) and underlying synaptic and cellular mechanisms. 2022 , 221, 109292	0
91	Effects of Perampanel on Seizure Control, Cognition, Behavior, and Psychological Status in Patients With Epilepsy: A Systematic Review. 2022 , 18, 653	O
90	Anti-convulsant Agents: Beginning, Maintenance, Pharmacoresistance, Duration of Therapy, and Withdrawal [Adults. 2022 , 3463-3472	O
89	Effectiveness and tolerability of lacosamide in children with drug-resistant epilepsy. 2022, 100574	O
88	Oxygenated Water Increases Seizure Threshold in Various Rodent Seizure Models. 2022 , 23, 14124	0
87	Performance evaluation of automotive dealerships using grouped mixture of regressions. 2022 , 119266	O
86	Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy. 13,	O
85	Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis. 2022 , 101732	O
84	Treatment-emergent adverse events and antiseizure medication actual drug load. 2022, 137, 108980	0
83	Unmet needs and perspectives in management of drug resistant focal epilepsy: An Italian study. 2022 , 137, 108950	O
82	Actual Telemedicine Needs of Japanese Patients with Neurological Disorders in the COVID-19 Pandemic. 2023 ,	0
81	Neurovascular coupling changes in patients with magnetic resonance imaging negative focal epilepsy. 2023 , 138, 109035	O
80	Clinical factors associated with late seizure remission after failed epilepsy surgery. 2023, 138, 109055	1
79	Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. 2023 , 360, 114288	O
78	Antiseizure medication withdrawal risk estimation and recommendations: a survey of American Academy of Neurology and EpiCARE members.	0
77	Clinical Outcome Data of Children Treated with Cannabis Based Medicinal Products for Treatment Resistant Epilepsy [Analysis from the UK Medical Cannabis Registry.	1

76	Time to Baseline Seizure Count in Patients with Focal Seizures Receiving Adjunctive Eslicarbazepine Acetate in a Phase IV Clinical Trial. 2022 , 107552	О
75	Treatment Outcomes of Newly Diagnosed Epilepsy: A Systematic Review and Meta-analysis.	Ο
74	Tetrapleura tetraptera curtails oxidative and proinflammatory biochemical events in lithium-pilocarpine model of status epilepticus.	0
73	Diagnosis and Treatment of Poststroke Epilepsy: Where Do We Stand?.	O
72	Rare genetic variation and outcome of surgery for mesial temporal lobe epilepsy.	0
71	Variation in access to specialist services for neurosurgical procedures in patients with epilepsy in England, a cohort study. 2022 ,	0
70	The WHO intersectoral global action plan and epilepsy cascade target: Towards a roadmap for implementation. 2022 , 103, 148-150	Ο
69	eTSC-Net: A Parameter-efficient Convolutional Neural Network for Drug Treatment Outcome Studies of Pediatric Epilepsy.	Ο
68	Vagus nerve stimulation in people with epilepsy and intellectual disabilityEnglish version. 2022 , 35, 123-126	0
67	Racial and Ethnic Differences in Antiseizure Medications Among People With Epilepsy on Medicaid. 2023 , 13, e200101	Ο
66	The neurovasculature as a target in temporal lobe epilepsy.	Ο
65	Autonomic dysfunction in epilepsy mouse models with implications for SUDEP research. 13,	O
64	Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy.	0
63	Neurotoxic A1 astrocytes promote neuronal ferroptosis via CXCL10/CXCR3 axis in epilepsy. 2023 , 195, 329-342	O
62	Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain. 2023 , 139, 109054	0
61	Implementing WHO's Intersectoral Global Action Plan for epilepsy and other neurological disorders in Southeast Asia: a´proposal. 2023 , 10, 100135	O
60	Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: a multicenter retrospective chart review.	O
59	Microwave Assisted Synthesis and Evaluation of Anticonvulsant Activity of Some 3-(3-(Substituted benzylidine)amino)phenyl-2-phenylquinazolin-4(3H)-ones. 2023 , 35, 95-98	Ο

58	Antiseizure medication withdrawal risk estimation and recommendations: a survey of American Academy of Neurology and EpiCARE members.	O
57	Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: a multicenter retrospective chart review.	O
56	Fighting Epilepsy with Nanomedicines This the Right Weapon?. 2023, 15, 306	1
55	Interaktionen zwischen anfallssupprimierenden Medikamenten und Empfehlungen fl Kombinationstherapien. 2023 , 94, 149-158	O
54	A pilot study on identifying gene signatures as markers for predicting patient response to antiseizure medications.	0
53	Antiseizure Medication Withdrawal Practice Patterns. 2023 , 13, e200109	O
52	Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.	О
51	Best-worst scaling preferences among patients with well-controlled epilepsy: Pilot results. 2023 , 18, e0282658	O
50	Selective Serotonin Reuptake Inhibitors and 5-HT2 Receptor Agonists Have Distinct, Sleep-state Dependent Effects on Postictal Breathing in Amygdala Kindled Mice. 2023 , 513, 76-95	О
49	Can the gut microbiota serve as a guide to the diagnosis and treatment of childhood epilepsy?. 2023 ,	O
48	Long-Term Pharmacological and Psychosocial Outcomes of Adolescent-Onset Epilepsy: A Single-Center Experience. 2023 , 31, 113-122	0
47	Personalised virtual brain models in epilepsy. 2023 , 22, 443-454	O
46	Epileptic-network-based prediction and control of seizures in humans. 2023 , 181, 106098	0
45	Deep brain stimulation of thalamus for epilepsy. 2023 , 179, 106045	O
44	Dietary intake and nutritional status of people with epilepsy: A systematic review. 2023 , 140, 109090	0
43	Experience of waiting for seizure freedom and perception of machine learning technologies to support treatment decision: A qualitative study in adults with recent onset epilepsy. 2023 , 190, 107096	O
42	Computing Drug-Drug Similarity from Patient-Centric Data. 2023 , 10, 182	O
41	Thalamic neuromodulation in epilepsy: A primer for emerging circuit-based therapies. 2023 , 23, 123-140	O

40	Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs. 2023, 24, 2928	1
39	Targeting adverse effects of antiseizure medication on offspring: current evidence and new strategies for safety. 2023 , 23, 141-156	O
38	Neuroinflammatory mediators in acquired epilepsy: an update.	2
37	????? ??????????. 2022 , 18, 317-322	O
36	???????. 2022 , 18, 354-359	O
35	Sudden unexpected death in epilepsy. 2023 , 36, 102-109	O
34	Recent advances in pharmacotherapy for epilepsy. 2023 , 36, 77-85	O
33	Prognostic interictal electroencephalographic biomarkers and models to assess antiseizure medication efficacy for clinical practice: A scoping review.	O
32	Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A Beal-world retrospective study.	0
31	Drosophila melanogaster as a versatile model organism to study genetic epilepsies: An overview. 16,	O
30	A patient-derived mutation of epilepsy-linked LGI1 increases seizure susceptibility through regulating Kv1.1. 2023 , 13,	O
29	Promising anticonvulsant N-[(2,4-dichlorophenyl) methyl]-2-(2,4-dioxo-1H-quinazolin-3-yl) acetamide: dose-dependent study and evaluation of anticonvulsant action spectrum in vivo and in silico. 2022 , 71, 224-233	O
28	Scoping review of disease-modifying effect of drugs in experimental epilepsy. 14,	О
27	Can machine learning solve this one? Clinical pitfalls in surgical outcome prediction.	O
26	Actualizacifi en el tratamiento de la epilepsia. 2023 , 13, 4230-4242	0
25	Interference of New Antiseizure Agents with Hospital Transfer of Stroke Patients in Japan: A Retrospective Cohort Study. 2023 , 46, 440-445	O
24	Failure to use new breakthrough treatments for epilepsy.	O
23	Frontline Sodium Channel-Blocking Antiseizure Medicine Use Promotes Future Onset of Drug-Resistant Chronic Seizures. 2023 , 24, 4848	O

22	Should substitution monotherapy or combination therapy be used after failure of the first antiseizure medication? Observations from a 30-year cohort study.	o
21	Impact of regulatory safety warnings and restrictions on drug treatment of epilepsy. 2023 , 22, 111-114	O
20	Spatial and Amplitude Dynamics of Neurostimulation: Insights from the Acute Intrahippocampal Kainate Seizure Mouse Model.	0
19	Corticosteroids in childhood epilepsies: A systematic review. 14,	О
18	Forming new connections: Advances in human stem-cell-derived interneuron therapy for treating epilepsy. 2023 , 111, 758-760	0
17	Pharmacologically targeting transient receptor potential channels for seizures and epilepsy: Emerging preclinical evidence of druggability. 2023 , 244, 108384	O
16	Under New Management: Transplanted GABAergic Progenitors Control Adult Neurogenesis. 1535759723	11606
15	Poo Matters! A scoping review of impact of constipation on epilepsy. 2023,	O
14	Brand Name Versus Generic?. 153575972311557	O
13	Adherence to and persistence with lacosamide, perampanel, lamotrigine, and levetiracetam in adult patients with focal epilepsy in Japan: A descriptive cohort study using a claims database. 2023 , 9, e15017	О
12	New insights for predicting surgery outcome in patients with temporal lobe epilepsy. A systematic review. 2023 ,	O
11	Personalized antiseizure medication therapy in critically ill adult patients.	O
10	Focal Cortex Stimulation With a Novel Implantable Device and Antiseizure Outcomes in 2 Prospective Multicenter Single-Arm Trials.	2
9	Should antiseizure medications be withdrawn after an extended period of seizure freedom in individuals with adult-onset epilepsy?. 2023 , 142, 109205	О
8	GluK2 is a target for gene therapy in drug-resistant Temporal Lobe Epilepsy.	0
7	Dynamics of AMPA receptors regulate epileptogenesis in patients with epilepsy. 2023 , 101020	О
6	Adverse Events of Cannabidiol Use in Patients With Epilepsy. 2023 , 6, e239126	O
5	Antiepileptic Properties of Scyllo-Inositol on Pentylenetetrazol-Induced Seizures. 2023 , 24, 7598	О

CITATION REPORT

Vagus nerve stimulation. 2023, 51-95

Intracerebroventricular administration for delivery of antiseizure therapeutics: Challenges and opportunities.

Ketogenic Diet in Children and Adolescents: the Effects on Growth and Nutritional Status. 2023, 106780

Adjunctive Use of Cannabidiol: A Joint Action to Patch Up Drug-Resistant Epilepsy. 153575972311695